Please assess the completion status of the following clinical trial:

Trial Title: Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women between the ages of 18-60 who meet DSM-IV criteria for current cocaine dependence and adult ADHD (DSM-IV-TR).~2. Used cocaine at least four days in the past month~3. Must have a Body Mass Index (BMI) \> 18 kg/m2~4. Alcohol Breathalyzer (BraC) at consent of \< 0.04%~5. Individuals must be capable of giving informed consent and capable of complying with study procedures.~6. Women of child bearing age will be included in the study provided that they are not pregnant, based on the results of a blood pregnancy test drawn at the time of screening. They must also agree to use a method of contraception with proven efficacy and agree not to become pregnant during the study. To confirm this, blood pregnancy tests will be repeated monthly. Women will be provided a full explanation of the potential dangers of pregnancy while on the study medication. If a woman becomes pregnant, the study medication will be discontinued.~Exclusion Criteria:~1. Meets DSM-IV-TR criteria for bipolar disorder, schizophrenia or any psychotic disorder other than transient psychosis due to drug abuse.~2. Individuals with any current Axis I psychiatric disorder as defined by DSM-IV-TR supported by the SCID-I/P that in the investigator's judgment are unstable or would be disrupted by study medication or are likely to require pharmacotherapy during the study period.~3. Individuals with current major depressive disorder.However,individuals who are currently stable on a psychotropic medication for three months with a HAM-D \<14 may be included.~4. Individuals physiologically dependent on any other drugs (excluding nicotine or cannabis) which require medical intervention.~5. Individuals with current suicidal risk.~6. Individuals with coronary vascular disease as indicated by history or suspected by abnormal ECG, cardiac symptoms, fainting, open-heart surgery and/or arrhythmia, and family history of ventricular tachycardia/sudden death.~7. Unstable physical disorders which might make participation hazardous such as uncontrolled hypertension (SBP \> 140, DBP\> 90, or HR \> 100 when sitting quietly), acute hepatitis (patients with chronic mildly elevated transaminases \< 3x upper limit of normal are acceptable), or uncontrolled diabetes.~8. Individuals with a history of seizures~9. History of allergic reaction to candidate medication (amphetamine and/or ER-MAS).~10. Women who are pregnant or nursing.~11. History of failure to respond to a previous adequate trial of the candidate medication for cocaine dependence~12. Individuals who are legally mandated (e.g., to avoid incarceration, monetary or other penalties, etc.) to participate in substance abuse treatment program~13. History of glaucoma~14. Individuals who report use of MAOI within 14 days of study start

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Adderall-XR 60 mg (Type: EXPERIMENTAL): Adderall-XR 60 mg
- Adderall-XR 80 mg (Type: EXPERIMENTAL): Adderall-XR 80 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).